Micropac Industries Inc. (MPAD) Financials Nov 14, 2014,

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
Micropac Industries Inc. (MPAD) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Micropac Industries Inc.


Fiscal year is December-November. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 17.57M 23.07M 20.21M 17.7M 19.68M
Cost of Goods Sold (COGS) incl. D&A 12.33M 14.6M 13.3M 12.59M 11.65M
COGS excluding D&A 12.07M 14.33M 12.98M 12.27M 11.33M
Depreciation & Amortization Expense 255,000 268,000 319,000 319,000 317,000
Depreciation 255,000 268,000 319,000 - 317,000
Amortization of Intangibles 0 0 0 - 0
Gross Income 5.24M 8.47M 6.9M 5.11M 8.03M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 4.06M 4.47M 4.49M 4.41M 5.59M
Research & Development 639,000 455,000 610,000 574,000 1.54M
Other SG&A 3.42M 4.02M 3.88M 3.84M 4.05M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 0 0 0 338,000
EBIT after Unusual Expense 0 0 0 0 (338,000)
Non Operating Income/Expense 58,000 117,000 95,000 79,000 39,000
Non-Operating Interest Income 20,000 3,000 0 0 3,000
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 0 0 0 0 0
Gross Interest Expense 0 0 0 0 0
Interest Capitalized - 0 0 0 0
Pretax Income 1.27M 4.12M 2.51M 782,000 2.14M
Income Tax 449,000 1.42M 868,000 326,000 746,000
Income Tax - Current Domestic 765,000 1.2M 532,000 214,000 842,000
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic (316,000) 216,000 336,000 112,000 (96,000)
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) - - 0 0 0
Consolidated Net Income 817,000 2.7M 1.64M 456,000 1.39M
Minority Interest Expense 0 0 0 0 0
Net Income 817,000 2.7M 1.64M 456,000 1.39M
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 817,000 2.7M 1.64M 456,000 1.39M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 817,000 2.7M 1.64M 456,000 1.39M
EPS (Basic) 0.32 1.05 0.64 0.18 0.54
Basic Shares Outstanding 2.58M 2.58M 2.58M 2.58M 2.58M
EPS (Diluted) 0.32 1.05 0.64 0.18 0.54
Diluted Shares Outstanding 2.58M 2.58M 2.58M 2.58M 2.58M
EBITDA 1.44M 4.26M 2.74M 1.02M 2.75M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Rate and Betterment's Mortgage Play: Savings or Spin?

Updated Category News Views 151

So here’s the scoop: Rate just teamed up with Betterment on February 17, 2026, offering some pretty slick mortgage incentives for those sitting on at least $100K in their investment accounts. But let’s dig into the nitty-gritty before you start dreaming of that low-rate home loan. Betterment's Strategy: Solid Gains or Hype? The partnership aims to deliver discounted...

Continue Reading
UK Water Companies Gain Confidence After Regulatory Update

Updated Category News Views 253

Morgan Stanley Highlights UK Water Sector Improvements Investment risks surrounding listed UK water companies have significantly decreased following a key regulatory decision concerning water bill increases in England and Wales. According to analysts from Morgan Stanley, this development has created a more favorable landscape for investors in the sector. Key Insights From...

Continue Reading
SiLC Technologies Unveils Advanced Eyeonic Trace Scanner

Updated Category News Views 228

SiLC Technologies Introduces Eyeonic Trace Laser Line Scanner SiLC Technologies, a leader in the development of advanced integrated FMCW LiDAR solutions, recently announced an exciting new product: the Eyeonic Trace Laser Line Scanner. This state-of-the-art Class 1 Laser Line Scanner is engineered to achieve precise measurements of objects from distances of up to 10...

Continue Reading
Accord BioPharma Launches HERCESSI™ for Cancer Treatment

Updated Category News Views 94

Accord BioPharma Announces FDA Approval for HERCESSI™ Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, has achieved a major milestone in cancer treatment with the FDA's approval of a new 420mg strength of HERCESSI™ (trastuzumab-strf). This biosimilar to Herceptin (trastuzumab) targets different types of HER2-overexpressing cancers, such as...

Continue Reading
Why Oklo Stock is Soaring This Week and What to Expect

Updated Category News Views 493

What’s Driving Oklo Inc’s Stock Surge? Oklo Inc (NYSE: OKLO) is making waves in the stock market as its shares witness impressive growth. Over the past month, the company has experienced a remarkable rally of approximately 60%. Investors are keen to learn about the driving forces behind this upward trend. Recent Positive Developments This recent surge can primarily be...

Continue Reading